MARKET

CNTA

CNTA

Centessa Pharmaceuticals Plc
NASDAQ
23.69
-1.32
-5.28%
After Hours: 23.69 0 0.00% 16:10 01/02 EST
OPEN
24.88
PREV CLOSE
25.01
HIGH
25.21
LOW
23.49
VOLUME
783.71K
TURNOVER
--
52 WEEK HIGH
30.58
52 WEEK LOW
9.60
MARKET CAP
3.46B
P/E (TTM)
-12.9844
1D
5D
1M
3M
1Y
5Y
1D
Centessa Pharmaceuticals Is Maintained at Buy by Chardan Capital
Dow Jones · 1d ago
3 ‘Strong Buy’ Stocks to Buy Now, 1/1/2026, According to Top Analysts
TipRanks · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Palisade Bio (PALI), Centessa Pharmaceuticals (CNTA)
TipRanks · 2d ago
Weekly Report: what happened at CNTA last week (1222-1226)?
Weekly Report · 12/29/2025 10:21
These Are the Most and Least Likely Biotech Takeover Targets for 2026
TipRanks · 12/23/2025 19:37
Here are the most and least likely M&A targets in biotech, according to Truist
Seeking Alpha · 12/23/2025 18:26
How Elevating Orexin Program Leader to CEO Could Reshape Centessa Pharmaceuticals' (CNTA) Strategic Focus
Simply Wall St · 12/23/2025 01:14
Weekly Report: what happened at CNTA last week (1215-1219)?
Weekly Report · 12/22/2025 10:21
More
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

Webull offers Centessa Pharmaceuticals PLC - ADR stock information, including NASDAQ: CNTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTA stock methods without spending real money on the virtual paper trading platform.